Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow IGC Pharma, Inc.

Get SEC filing alerts via email and in your feed for IGC Pharma, Inc.

IGC

IGC Pharma, Inc.

About IGC Pharma, Inc.

IGC Pharma Inc. develops innovative therapies targeting Alzheimer’s disease and neurodegenerative disorders. Its core focus is on advancing drug candidates like IGC-AD1 for agitation and sleep disturbances in Alzheimer’s patients, utilizing AI for early detection and personalized treatment. The company leverages proprietary IP, conducts clinical trials, and operates in global markets, aiming to deliver safe, effective, and differentiated CNS therapies.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from IGC Pharma, Inc.

1
1
IGC Pharma, Inc. IGC Pharma Reports Decrease in Revenue and Increased Net Loss for Quarter Ending March 31, 2026

Via official filing (AI summary) | 19 days ago | 0 comments

2
1
IGC Pharma, Inc. IGC Pharma Reports Revenue Decline to $191,000 Amid Strategic Focus on Clinical Trials

Via official filing (AI summary) | 7 months ago | 0 comments

3
1
IGC Pharma, Inc. IGC Pharma Reports 21% Revenue Growth and Improved Net Loss for Quarter Ending June 30, 2025

Via official filing (AI summary) | 10 months ago | 0 comments

4
1
IGC Pharma, Inc. IGC Pharma Reports $7.1 Million Net Loss, Focuses on Alzheimer’s Drug Development

Via official filing (AI summary) | 11 months ago | 0 comments

5
1
IGC Pharma, Inc. IGC Pharma Reports Revenue Increase for Q3 2024, Despite Nine-Month Decline

Via official filing (AI summary) | over 1 year ago | 0 comments

6
1
IGC Pharma, Inc. IGC Pharma Reports 42% Revenue Growth, Improved Profitability, and Advancements in Clinical Pipeline

Via official filing (AI summary) | over 1 year ago | 0 comments